Altimmune (ALT) Deferred Taxes (2012 - 2025)

Altimmune's (ALT) quarterly Deferred Taxes came in at -$681000.0 in Q1 2025, up 92.6% on a QoQ basis from -$9.2 million in Q4 2018.

Altimmune (ALT) Deferred Taxes (2012 - 2025) Analysis & Trends

Altimmune (ALT) has 8 years of Deferred Taxes data on file, last reported at -$681000.0 in Q1 2025.

On a quarterly basis, Deferred Taxes changed N/A year-over-year to -$681000.0 in Q1 2025; TTM through Dec 2025 was -$681000.0, a N/A change from a year earlier, with the FY2025 full-year figure at -$681000.0, changed N/A from the prior year.
Deferred Taxes for Q1 2025 stood at -$681000.0, up from -$9.2 million in the prior quarter.
Over the last five years, Deferred Taxes for ALT reached as high as -$681000.0 in Q1 2025 and fell as low as -$681000.0 in Q1 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Deferred Taxes (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn	-
4	NuCana	279.75 Bn	279.75 Bn	-	-188,883.60
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn	-65.30 Mn
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn	96.00 Mn
7	Belite Bio	62.51 Bn	62.51 Bn	-	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn	-
9	Revolution Medicines	37.78 Bn	37.78 Bn	-	-
10	Altimmune	7.96 Mn	7.96 Mn	-	-

Download Data